Big Pharma cashes in on HGH abuse

December 21, 2012 by David B. Caruso

An Associated Press investigation shows that a federal crackdown on illicit foreign supplies of human growth hormone has failed to stop rampant misuse, and instead has driven record sales of the drug by some of the world's biggest pharmaceutical companies.

The crackdown, which began in 2006, reduced the illegal flow of unregulated supplies from China, India and Mexico. But since then, Big Pharma has been satisfying the steady desires of U.S. users and abusers, including many who take the drug in the false hope of delaying aging.

An AP analysis of pharmaceutical company data shows that from 2005 to 2011, inflation-adjusted sales of HGH were up 69 percent. During the same period, sales of the average prescription drug rose 12 percent.

Under U.S. law, HGH can only be dispensed for very rare conditions.

Explore further: US drug sales growth continues slowdown in 2008

shares

Related Stories

Data firm sees 2011 drug sales rising 5-7 percent

October 7, 2010

(AP) -- Revenue from global prescription drug sales should increase 5 percent to 7 percent next year, reaching at least $880 billion, fueled by new drugs and rising sales in developing countries, according to drug data firm ...

Global spending on drugs to slow through 2016

July 12, 2012

(AP) — Growth in global spending on medications will slow markedly over the next four years due to a large number of new low-cost generic drugs coming to pharmacies in the U.S. and other developed countries, along with ...

J&J Q3 net income drops 7 percent on higher costs

October 16, 2012

Johnson & Johnson's third-quarter profit fell 7 percent as increased research and production costs offset higher sales for its medicines and medical devices and new revenue from its biggest acquisition ever.

Recommended for you

Non-addictive painkiller shows promise in animal trials

August 30, 2016

(HealthDay)—Preliminary research in monkeys suggests that a new medication might be able to provide pain relief similar to opioid drugs such as OxyContin, but without the same potential for addiction or serious side effects.

Mylan launching cheaper, generic version of EpiPen

August 29, 2016

The maker of EpiPens will start selling a cheaper, generic version of the emergency allergy shots as the furor over repeated U.S. price hikes continues—and looming competition threatens its near-monopoly.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.